193 related articles for article (PubMed ID: 27497686)
1. Trivalent chromium alleviates oleic acid induced steatosis in SMMC-7721 cells by decreasing fatty acid uptake and triglyceride synthesis.
Wang S; Wang J; Zhang X; Hu L; Fang Z; Huang Z; Shi P
Biometals; 2016 Oct; 29(5):881-92. PubMed ID: 27497686
[TBL] [Abstract][Full Text] [Related]
2. Trivalent Chromium Supplementation Ameliorates Oleic Acid-Induced Hepatic Steatosis in Mice.
Wang S; Wang J; Liu Y; Li H; Wang Q; Huang Z; Liu W; Shi P
Biol Trace Elem Res; 2019 Jan; 187(1):192-201. PubMed ID: 29797206
[TBL] [Abstract][Full Text] [Related]
3. Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis.
Bai X; Hong W; Cai P; Chen Y; Xu C; Cao D; Yu W; Zhao Z; Huang M; Jin J
Toxicol Appl Pharmacol; 2017 Jun; 324():12-25. PubMed ID: 28366540
[TBL] [Abstract][Full Text] [Related]
4. Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro.
Ma L; Wang Y; Chen X; Zhao L; Guo Y
Toxicology; 2020 Dec; 445():152585. PubMed ID: 33007364
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
7. Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice.
Choi YJ; Lee CH; Lee KY; Jung SH; Lee BH
Toxicol Sci; 2015 Jun; 145(2):273-82. PubMed ID: 25745068
[TBL] [Abstract][Full Text] [Related]
8. CD36 and DGAT2 facilitate the lipid-lowering effect of chitooligosaccharides
Shen X; Liang X; Ji X; You J; Zhuang X; Song Y; Yin H; Zhao M; Zhao L
Food Funct; 2021 Sep; 12(18):8681-8693. PubMed ID: 34351342
[TBL] [Abstract][Full Text] [Related]
9. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
[TBL] [Abstract][Full Text] [Related]
10. The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2.
Qi J; Lang W; Geisler JG; Wang P; Petrounia I; Mai S; Smith C; Askari H; Struble GT; Williams R; Bhanot S; Monia BP; Bayoumy S; Grant E; Caldwell GW; Todd MJ; Liang Y; Gaul MD; Demarest KT; Connelly MA
J Lipid Res; 2012 Jun; 53(6):1106-16. PubMed ID: 22493088
[TBL] [Abstract][Full Text] [Related]
11. Study of Valproic Acid-Enhanced Hepatocyte Steatosis.
Chang R; Chou MC; Hung LY; Wang ME; Hsu MC; Chiu CH
Biomed Res Int; 2016; 2016():9576503. PubMed ID: 27034954
[TBL] [Abstract][Full Text] [Related]
12. Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis.
Patel TP; Rawal K; Soni S; Gupta S
Biomed Pharmacother; 2016 Oct; 83():785-791. PubMed ID: 27490779
[TBL] [Abstract][Full Text] [Related]
13. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.
Anthérieu S; Rogue A; Fromenty B; Guillouzo A; Robin MA
Hepatology; 2011 Jun; 53(6):1895-905. PubMed ID: 21391224
[TBL] [Abstract][Full Text] [Related]
14. A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis.
Wallstab C; Eleftheriadou D; Schulz T; Damm G; Seehofer D; Borlak J; Holzhütter HG; Berndt N
FEBS J; 2017 Oct; 284(19):3245-3261. PubMed ID: 28763157
[TBL] [Abstract][Full Text] [Related]
15. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver.
Monetti M; Levin MC; Watt MJ; Sajan MP; Marmor S; Hubbard BK; Stevens RD; Bain JR; Newgard CB; Farese RV; Hevener AL; Farese RV
Cell Metab; 2007 Jul; 6(1):69-78. PubMed ID: 17618857
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
Amin NB; Saxena AR; Somayaji V; Dullea R
Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
[TBL] [Abstract][Full Text] [Related]
18. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY
Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
Turkish AR
Curr Opin Clin Nutr Metab Care; 2008 Mar; 11(2):128-33. PubMed ID: 18301087
[TBL] [Abstract][Full Text] [Related]
20. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Choi SS; Diehl AM
Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
